PVI
CCCC icon

Pura Vida Investments’s C4 Therapeutics CCCC Stock Holding History

Pura Vida Investments’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200,000
Closed -$4.85M – 220
2022
Q1 		$4.85M Buy
+200,000
New +$4.86M 0.16% 125

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Pura Vida Investments's CCCC Position: Q2 2022 in Review

Pura Vida Investments sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 624,860 shares — an estimated $15.2M sold.

Pura Vida Investments first reported a position in CCCC in Q3 2021 and held it in 3 quarters. The position peaked at $15.2M in Q1 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Pura Vida Investments reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 624,860 C4 Therapeutics shares in Q2 2022, an estimated $15.2M.
  • Pura Vida Investments first reported a position in C4 Therapeutics in Q3 2021 and held it in 3 quarters.
  • Pura Vida Investments's C4 Therapeutics position peaked at $15.2M in Q1 2022.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.